Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005788 · ClinicalTrials.gov registry record · Phase 2
Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00005788: Clinical Trial Phase 2 study, sponsored by Northwestern University.
NCT00005788 is a Phase 2 study that was terminated before completion, run by Northwestern University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005788, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides or Sezary syndrome.
Interventions
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-04 |
| Est. Completion | 2002-01 |
| Phase | Phase 2 |
Why NCT00005788 stopped before completion
NCT00005788 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which aldesleukin is the first listed.
NCT00005788 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005788 about?
NCT00005788 is a clinical study titled "Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides or Sezary syndrome.
What is the current status of trial NCT00005788?
This trial is currently terminated. It is a Phase 2 study. The study started on 1997-04. Estimated completion is 2002-01.
What interventions are being tested in trial NCT00005788?
The interventions under investigation include: aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005788?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia